Paul from Austria

Registered at the short selling broker Skilling, 5 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Takeda Pharmaceutical Co., Ltd (TAK) shares information

Takeda Pharmaceutical Co., Ltd.

24h Change

0.48 %


Live rate: Market closed

Stock data per Monday 19 Oct, 2020

New York Stock Exchange
0.08 (+ 0.48%)
US Market is closed

Live Stock price in graph for Takeda Pharmaceutical Co., Ltd. (TAK)

  • Latest Volume

    1,120,344 (0.69 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high


  • 52 week low


  • YTD Change


Quick links

Broker recommendations for Takeda Pharmaceutical Co., Ltd

The Takeda Pharmaceutical Co., Ltd stock is rated at 1.230769 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Friday 25 September, 2020 by a total of 13 brokers. This means that the consensus of the 13 different brokers is leaning toward to buy/moderate buy.

0 (0%)
0 (0%)
2 (15.38%)
2 (15.38%)
9 (69.23%)

Price target by analysts

The 12 latest analyst estimates, per Saturday 17 October, 2020, show the following high, low and average price targets.
Target Average: 25.1 USD
Target High: 30.63 USD
Target Low: 19.37 USD


Latest news about Takeda Pharmaceutical Co., Ltd.

Below you can find the most recent news posts about Takeda Pharmaceutical Co., Ltd., primarily from US and UK based news sources.

Sleeping Medications Market COVID-19 Impact, Global Analysis and Forecast to 2027| Pfizer, Sanofi, Sumitomo Dainippon Pharma Co., Takeda Pharmaceutical Company Ltd., Teva Pharmaceutical Industries Ltd.

Thursday, 15 October 2020, 20:29:28
Sleeping medications are known as sleeping pills. Sleeping pills mainly refers to a generic term that is used for describing both over-the-counter (OTC) or prescription medications. Sleeping pills are majorly used for helping individuals who face difficulty in falling asleep
— OpenPR

Japan stocks fall as risks on several fronts unsettle investors

Thursday, 15 October 2020, 10:29:41
The biggest underperformers among the top 30 core Topix names were venture capitalist SoftBank Group Corp, down 2.08%, followed by drugs maker Takeda Pharmaceutical Co Ltd losing 1.97%.
— Economic Times India

Next Generation Bio-therapeutics Market Insights 2020: Business Analysis By 2026 With Leading Players Takeda Pharmaceutical Company Limited, AstraZeneca, F. Hoffmann-La Roche Ltd

Tuesday, 13 October 2020, 20:45:40
Data Bridge Market Research recently introduced Global Next Generation Bio-therapeutics Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2026. The market Study is segmented by key regions which is accelerating
— OpenPR

Non-Small Cell Lung Cancer Market (COVID – 19 Updates) 2020 to See Stunning Growth Worldwide, Leading Players -Takeda Pharmaceutical Company Limited (Japan), Ono Pharmaceutical Co., Ltd. (Japan), F. Hoffmann-La Roche Ltd (Switzerland)

Tuesday, 13 October 2020, 20:41:02
Data Bridge Market Research has recently added a concise research on the Global Non-Small Cell Lung Cancer Market – Industry Trends and Forecast to 2026. Global Non-Small Cell Lung Cancer Market research report has been prepared with a nice combination
— OpenPR

Takeda Pharmaceutical : Accelerates Digital Transformation with Accenture and AWS | MarketScreener

Tuesday, 13 October 2020, 13:03:01
Collaboration will leverage cloud and data-driven insights to accelerate drug development, increase operational agility, reduce technology costs and develop the workforce of the future … | October 13, 2020
— MarketScreener

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €/$ 20
Description: offer a large number of stocks for trading. Register an account today and check if they have TAK available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.